Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).

• Donepezil Hydrochloride (Drug), also known as Aricept: Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.

Primary outcomes

• Mean Mini-Mental State Examination (MMSE) score [At Week 12]
• Mean Mini-Mental State Examination (MMSE) score [At Week 24]
• Mean Mini-Mental State Examination (MMSE) score [At Week 52]
• Mean Revised Hasegawa's Dementia Scale (HDS-R) score [At Week 12]
• Mean Revised Hasegawa's Dementia Scale (HDS-R) score [At Week 24]
• Mean Revised Hasegawa's Dementia Scale (HDS-R) score [At Week 52]

Secondary outcomes

• Number of participants with adverse events (AEs) /adverse drug reactions (ADRs) [From Week 0 to Week 52]

Sex: All

Inclusion Criteria:

1\. Naive participants diagnosed as DLB

Exclusion Criteria:

1. Participants with a history of donepezil hydrochloride product administration in the past
2. Participants who have already been registered in this surveillance
3. Participants with a history of hypersensitivity to any ingredients of donepezil hydrochloride or piperidine derivatives

• Kazuhiro Omata, Study director, Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd.
• Syoya Yamakawa, Study director, Drug Fostering and Evolution Coordination Department, Corporate Medical Affairs Headquarters, Eisai Co., Ltd.